The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

This multicentre real-world study evaluated the efficacy of targeted therapies in Turkish patients with metastatic squamous cell lung carcinoma harbouring driver mutations. Sixty-four patients with alterations such as EGFR, ALK, and ROS1 who received targeted agents were retrospectively analysed. EGFR mutations were most common (67.2%). Among EGFR-TKI-treated patients, median progression-free survival (PFS) and overall survival (OS) were 12.4 and 14.3 months, respectively. Alectinib yielded a median PFS of 18.6 months and OS of 29.8 months in ALK-positive patients, while crizotinib produced a median PFS and OS of 7 months in ROS1-positive patients. The overall response rate was 50% and the disease control rate 84.4%. Although targeted therapies prolonged PFS compared with chemotherapy, this improvement did not translate into a significant OS advantage, likely influenced by retrospective design and treatment crossover. Findings represent real-world outcomes in a molecularly defined subgroup.

Authors

Institutions

Publication Details

Journal
Journal of Chemotherapy
Published
2025-12-19
DOI
https://doi.org/10.1080/1120009x.2025.2601938
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

Muhammet Bekir Hacıoğlu, Gamze Gököz Doğu, Bilgeşah Kılıçtaş, Murat Arcagök et al.
Journal of Chemotherapy
Lung Cancer Treatments and Mutations
article

The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

Muhammet Bekir Hacıoğlu, Gamze Gököz Doğu, Bilgeşah Kılıçtaş, Murat Arcagök, Abdülkadir Koçanoğlu, Atila Yıldırım, Orhun Akdoğan, Adem Deligönül, Oğuzcan Kınıkoğlu, Berna Çakmak Öksüzoğlu, Atike Pınar Erdoğan, Mevlüde İnanç, Goncagül Akdağ, Teoman Şakalar, Tuğba Akın Telli, Dilek Çağlayan, Mehmet Artaç, Murat Araz, Mükremın Uysal, Ahmet Fatih Oruç, Ali Alkan, Zuhat Urakçı, Mahmut Büyükşimşek, Deniz Işık, Melek Karakurt Eryılmaz, Elif Şahin, Buket Erkan Özmarasalı, Galip Can Uyar, Ahmet Kürşad Dişli, Gamze Serin Özel, Tayyip İlker Aydın, Nilüfer Avcı, Ece Şahin Hafızoğlu, Gamze Emin, Yurdagül Danacı
article en

Abstract

This multicentre real-world study evaluated the efficacy of targeted therapies in Turkish patients with metastatic squamous cell lung carcinoma harbouring driver mutations. Sixty-four patients with alterations such as EGFR, ALK, and ROS1 who received targeted agents were retrospectively analysed. EGFR mutations were most common (67.2%). Among EGFR-TKI-treated patients, median progression-free survival (PFS) and overall survival (OS) were 12.4 and 14.3 months, respectively. Alectinib yielded a median PFS of 18.6 months and OS of 29.8 months in ALK-positive patients, while crizotinib produced a median PFS and OS of 7 months in ROS1-positive patients. The overall response rate was 50% and the disease control rate 84.4%. Although targeted therapies prolonged PFS compared with chemotherapy, this improvement did not translate into a significant OS advantage, likely influenced by retrospective design and treatment crossover. Findings represent real-world outcomes in a molecularly defined subgroup.

Journal of Chemotherapy
Dicle University (TR), Trakya University (TR), Lahey Hospital and Medical Center (US), Karadeniz Technical University (TR), Manisa Celal Bayar University (TR), Bursa Technical University (TR), Inonu University (TR), Turkish Armed Forces (TR), State Hospital (GB), Ankara Atatürk Eğitim ve Araştırma Hastanesi (TR), Antalya Bilim University (TR), Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR), Necmettin Erbakan University (TR), Memorial Sisli Hospital (TR), Gazi Hastanesi (TR), Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi (TR), Kahramanmaraş Sütçü İmam University (TR), Pamukkale University (TR), Kocaeli Üniversitesi (TR), Muğla University (TR), Erciyes University (TR), Gazi University (TR)
Openalex Percentile: Top 40%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.